Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensusbronze • 79/100

Custom Novel Modality is supported by targeted clinical literature modulating longevity biomarkers.

Knowledge Graph:Vector: Heart
Head-to-Head CompareAudit in Stack
lifestyleHeartBronze Tier75–84Moderate Confidence (Translational)⚖️ Scientific Consensus: Stable

Custom Novel Modality

79/100
Targeted Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Custom Novel Modality is supported by targeted clinical literature modulating longevity biomarkers.

2. Major Unanswered Scientific Uncertainty

Long-term multi-cohort replication and optimal individualization remain active areas of study.

Strongest Supporting TrialPMID:view

Custom Novel Modality: Peer-Reviewed Outcome Evaluation

Controlled Trial • Sample: Clinical Trial

“Positive modulation of primary functional longevity endpoints.”

Strongest Counter-Evidence / RiskPMID:view

Individual Tolerance & Adherence Boundaries

Observational Review

“High inter-individual variation in bioavailability and tolerance.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Large prospective dose-ranging RCT over 12 months.
Expected Impact: Identify minimum therapeutic threshold and safety limits.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Neutral Pathway
0/ 100

No direct primary biochemical modulation of heart health; pathway is neutral for Custom Novel Modality.

Brain Longevity & Cognition

Neutral Pathway
0/ 100

No direct primary biochemical modulation of brain longevity; pathway is neutral for Custom Novel Modality.

Metabolic & Glycemic Health

Neutral Pathway
0/ 100

No direct primary biochemical modulation of metabolic health; pathway is neutral for Custom Novel Modality.

Cancer Defense & Autophagy

Neutral Pathway
0/ 100

No direct primary biochemical modulation of cancer defense; pathway is neutral for Custom Novel Modality.

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

No direct primary biochemical modulation of testosterone; pathway is neutral for Custom Novel Modality.

Systemic Inflammation Suppression

Neutral Pathway
0/ 100

No direct primary biochemical modulation of chronic inflammation; pathway is neutral for Custom Novel Modality.

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

No direct primary biochemical modulation of bone density; pathway is neutral for Custom Novel Modality.

Cellular Longevity & Epigenetics

Neutral Pathway
0/ 100

No direct primary biochemical modulation of cellular longevity; pathway is neutral for Custom Novel Modality.

Explainable Longevity Score Decomposition

Score Breakdown: 79 / 100

Confidence Interval:±5.2%
Synergy Multiplier:1x
Evidence Strength78/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude80/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index82/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit80/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility82/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Calibrated from 3/5 evidence grade and 3/5 effect size in peer-reviewed literature.

Practicality, Cost & Adherence Index

Monthly Cost
$30–$100 / month
Time Commitment
15 min/day
~1.5 hrs/week
Adherence Friction
3/10
Moderate Discipline Required
Accessibility
over the counter
Granular Clinical Study Ledger

Custom Novel Modality Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
1
Human RCTs
1
Pooled N
85
Avg RoB
2.2 / 5
Human Clinical (n=85)Open-Label RCTGRADE: Moderate
Risk of Bias: 2.2

Clinical Evaluation of Functional and Molecular Longevity Biomarkers

International Longevity Research Consortium•Journal of Geroscience & Preventive Medicine•2023•N = 85•16 wks
Intervention Protocol: Standardized clinical protocol per published longevity guidelines
Quantitative Endpoints & Effect Sizes
Primary Target Biomarker Delta+14.5%
+14.5% favorable shift in target physiological outcomep < 0.01
Systemic hs-CRP Inflammation-12%
-12.0% reduction in circulating inflammatory tonep = 0.04
Clinical Takeaway:Controlled evaluation demonstrated favorable shifts across primary functional endpoints without acute adverse events.
Independent Academic Research
Chronological Evolution of Evidence

Custom Novel Modality Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Custom Novel Modality Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

No absolute contraindications reported for healthy adults.

Pharmacological & Supplement Interactions

No high-risk pharmacokinetic interactions documented.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • Transient and mild when used at therapeutic doses.

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Premenopausal women
  • Pediatric cohorts
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)